<DOC>
	<DOCNO>NCT01048463</DOCNO>
	<brief_summary>Malnutrition frequently see patient chemotherapy suffer gastric/colorectal cancer may worsen outcome . EPA , sort ω-3 PUFA , modulate immune system . EPA also antagonize metabolic inflammatory change induce tumor . This study test whether EPA , combination enteral nutrition , improve nutritional/immunologic status , quality life , reduce chemotherapy related side effect patient .</brief_summary>
	<brief_title>Effect Enteral Nutrition Rich Eicosapentaenoic Acid ( EPA ) Patients Receiving Chemotherapy GI Tumor</brief_title>
	<detailed_description>Chemotherapy indispensible patient suffer advanced gastric colorectal cancer , also main therapy end-stage tumor . However , incidence malnutrition chemotherapy report high 60 % . The mechanisms include anatomy modification digestive tract , side effect chemotherapy anorexia , nausea , vomit , inflammatory factor generate induced tumor . Malnutrition may lead discontinuation therapy , compromise anti-cancer effect , increase toxicity mortality . 20 % -40 % patient end-stage tumor ultimately die malnutrition . EPA ( Eicosapentaenoic acid , molecular formula C20H30O2 ) belong ω-3 polyunsaturated fatty acid ( ω-3 PUFA ) . EPA one main constituent fish oil . EPA decrease LPS-stimulated macrophage production TNF-α , IL-1β , IL-6 , human B lymphocytes production IL-10 , TNF-α , IFN-γ . EPA suppress cancer induce lipolysis , enhance inhibitory effect 5-Fu cancer cell proliferation . However , cancer patient always lack EPA . Nutriall sort non-elemental diet . The kind powder produce Guangdong Academy Agriculture Science . Every 50 gram nutriall contain 9.3mg VitC 0.8mg VitE . For enteral nutrition preparation , evidence protective effect nutritional status chemotherapy lung cancer . However , kind preparation contain EPA . Up date , RCT testify whether therapeutic dosage EPA plus enteral nutrition combine effect patient receive chemotherapy . The investigator choose nutriall basic nutritional support agent chemotherapy , give patient different dosage EPA . Nutritional immunologic status , quality life side effect chemotherapy record evaluate whether EPA improve outcome patient . Through study investigator may also optimize dose EPA patient receive chemotherapy gastric/colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>The case undergone radical excision gastric cancer colorectal cancer . Without contraindication chemotherapy . Eligible postoperative adjuvant XELOX chemotherapy . Capable take food drug orally . Without severe absorption dysfunction Able willing give write , informed consent Comorbidities : disease hematology immunology system ; hepatic renal dysfunction ; metabolic disease . BMI &gt; 35kg/m2 Life expectancy≤3mo The chemotherapy treatment palliative . The patient receive radiotherapy neoadjuvant chemotherapy prior operation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>eicosapentaenoic acid</keyword>
	<keyword>enteral nutrition</keyword>
</DOC>